{"disease":{"id":"childhood-fibrolamellar-carcinoma","name":"childhood fibrolamellar carcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03533582","title":"Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":537,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT06620302","title":"Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":81,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT04134559","title":"Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"Allison O'Neill, MD","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}